menu ☰
menu ˟

[Correspondence] Global platform to inform investments for health R&D

19 Mar 2016

Investments in health research and development (R&D) are still insufficiently aligned with global public health demands and needs. As little as 1% of all global funding for health R&D is allocated to diseases mostly noted in low-income and middle-income countries, such as malaria and tuberculosis,1 even though these diseases account for more than 12·5% of the global burden of disease.2 The 2014–15 Ebola outbreak exposed the paucity of investment in products and approaches to prevent and minimise the effect of pathogens with epidemic potential.

Click here to view the full article which appeared in The Lancet